These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 19587364)

  • 1. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.
    Perreault L; Kahn SE; Christophi CA; Knowler WC; Hamman RF;
    Diabetes Care; 2009 Sep; 32(9):1583-8. PubMed ID: 19587364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
    Perreault L; Pan Q; Mather KJ; Watson KE; Hamman RF; Kahn SE;
    Lancet; 2012 Jun; 379(9833):2243-51. PubMed ID: 22683134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
    Herman WH; Pan Q; Edelstein SL; Mather KJ; Perreault L; Barrett-Connor E; Dabelea DM; Horton E; Kahn SE; Knowler WC; Lorenzo C; Pi-Sunyer X; Venditti E; Ye W;
    Diabetes Care; 2017 Dec; 40(12):1668-1677. PubMed ID: 29021207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.
    Pratte KA; Johnson A; Beals J; Bullock A; Manson SM; Jiang L;
    Diabetes Care; 2019 Jul; 42(7):1209-1216. PubMed ID: 31177184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
    Kitabchi AE; Temprosa M; Knowler WC; Kahn SE; Fowler SE; Haffner SM; Andres R; Saudek C; Edelstein SL; Arakaki R; Murphy MB; Shamoon H;
    Diabetes; 2005 Aug; 54(8):2404-14. PubMed ID: 16046308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.
    Goldberg R; Temprosa M; Otvos J; Brunzell J; Marcovina S; Mather K; Arakaki R; Watson K; Horton E; Barrett-Connor E
    J Clin Endocrinol Metab; 2013 Oct; 98(10):3989-98. PubMed ID: 23979954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcohol consumption and diabetes risk in the Diabetes Prevention Program.
    Crandall JP; Polsky S; Howard AA; Perreault L; Bray GA; Barrett-Connor E; Brown-Friday J; Whittington T; Foo S; Ma Y; Edelstein SL;
    Am J Clin Nutr; 2009 Sep; 90(3):595-601. PubMed ID: 19640960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).
    Sandforth A; von Schwartzenberg RJ; Arreola EV; Hanson RL; Sancar G; Katzenstein S; Lange K; Preißl H; Dreher SI; Weigert C; Wagner R; Kantartzis K; Machann J; Schick F; Lehmann R; Peter A; Katsouli N; Ntziachristos V; Dannecker C; Fritsche L; Perakakis N; Heni M; Nawroth PP; Kopf S; Pfeiffer AFH; Kabisch S; Stumvoll M; Schwarz PEH; Hauner H; Lechner A; Seissler J; Yurchenko I; Icks A; Solimena M; Häring HU; Szendroedi J; Schürmann A; de Angelis MH; Blüher M; Roden M; Bornstein SR; Stefan N; Fritsche A; Birkenfeld AL
    Lancet Diabetes Endocrinol; 2023 Nov; 11(11):798-810. PubMed ID: 37769677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin use in prediabetes: is earlier intervention better?
    Warrilow A; Somerset S; Pumpa K; Fleet R
    Acta Diabetol; 2020 Nov; 57(11):1359-1366. PubMed ID: 32601731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight Loss, Lifestyle Intervention, and Metformin Affect Longitudinal Relationship of Insulin Secretion and Sensitivity.
    Vazquez Arreola E; Knowler WC; Hanson RL
    J Clin Endocrinol Metab; 2022 Nov; 107(11):3086-3099. PubMed ID: 36062951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.
    ; Crandall J; Schade D; Ma Y; Fujimoto WY; Barrett-Connor E; Fowler S; Dagogo-Jack S; Andres R
    J Gerontol A Biol Sci Med Sci; 2006 Oct; 61(10):1075-81. PubMed ID: 17077202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
    Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
    Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
    Apolzan JW; Venditti EM; Edelstein SL; Knowler WC; Dabelea D; Boyko EJ; Pi-Sunyer X; Kalyani RR; Franks PW; Srikanthan P; Gadde KM;
    Ann Intern Med; 2019 May; 170(10):682-690. PubMed ID: 31009939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in the prevention of type 2 diabetes].
    Schernthaner G
    Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
    Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
    Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
    Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
    Goldberg RB; Temprosa M; Haffner S; Orchard TJ; Ratner RE; Fowler SE; Mather K; Marcovina S; Saudek C; Matulik MJ; Price D;
    Diabetes Care; 2009 Apr; 32(4):726-32. PubMed ID: 19171717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
    Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
    Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.